EMA Authorised: Advagraf (tacrolimus) — Astellas Pharma Europe BV

View source ↗

Summary

The EMA authorized Advagraf (tacrolimus) by Astellas Pharma Europe BV for prevention of graft rejection in organ transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Organ Transplant Rejection
• Organ Transplantation

Drugs mentioned

• Advagraf (tacrolimus)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Astellas Pharma Europe BV. Decision date: 12/02/2025